Key Lessons from the TNF Inhibitor Head-to-Head EXXELERATE Study

Save

The EXXELERATE study is featured prominently in Lancet this week. In some ways, this represents a landmark negative trial that rheumatologists should review and be aware of.

Is ABT-494 the Next JAK Inhibitor?

Save

Tofacitinib may well be joined by a new once daily JAK inhibitor, baricitinib in the next few months.

The RheumNow Week in Review – 2 December 2016

Save

Dr. Cush highlights reports from this week on RheumNow.com.

RheumNow (ACR16) Week in Review – 18 November 2016

Save

Epilepsy is More Likely in Offspring for Women with Rheumatoid Arthritis

Save

The offspring of women with rheumatoid arthritis (RA) may be at greater risk for the development of epilepsy, according to a recent report in the journal Neurology, suggesting that epileptogenic triggers may begin during pregnancy and may be wors

Dual Cytokine Inhibition for RA

Save

The notion of a single biologic targeting two cytokines is intriguing. ABT-122 is a new dual-variable domain immunoglobulin that neutralizes both TNF-α and IL-17A.

Celecoxib Shines and Naproxen Tanks in the PRECISION Study

Save

The PRECISION trial was published this week in the NEJM, presented at the Cardiology meetings in New Orleans, and presented today by Dr. Daniel Solomon at the 2016 ACR annual meeting in Washington, D.C. (citation source http://buff.ly/2fUmoqO)

Tocilizumab Infections Less in ACPA+ Patients

Save

Tocilizumab is in the spotlight at this year’s ACR 2016 meeting but there is still much to learn, including more about its safety profile. In an abstract presented at today’s poster session (Abstract 2618), Morel, et al.

ACR 2016 – Day 2 Highlights

Save

Big highlights from Monday included the Hench Lecture, plenary session abstracts and presentations on drug safety and cost efficacy in rheumatoid arthritis.

CORRONA Presentations at ACR 2016

Save

CORRONA, America's largest registry, has numerous presentations for this year's annual ACR/ARHP meeting. See below for the expanse of efficacy and safety issues covered by CORRONA investigators.

Two New Biologics for Polyarticular JIA

Save

On Monday, November 13, there were two new presentations at the annual ACR 2016 meeting on new biologics seeking approval for use in polyarticular juvenile arthritis.

RheumNow Week in Review – 11 November 2016

Save

Dr Cush reviews highlights from this week on RheumNow.com

The Long Awaited PRECISION Study

Save

The PRECISION study will be presented on Tuesday, November 15, 2016 by Dr. Elaine Husni from the Cleveland Clinic. This report brings to a climax the controversy ignited by the February 2005 3 day FDA Arthritis Advisory Committee review of the safety of the blockbuster COX-2 inhibitors, celecoxib, rofecoxib, and valdecoxib.

Pfizer Features Xeljanz Presentations at ACR 2016

Save

At this years 2016 ACR/ARHP Annual Meeting Pfizer will presen 20 abstracts, mostly centering around its JAK inhibitor tofacitinib (Xeljanz). They will also present the results of their Phase 3 OPAL studies of tofacitinib in patients with psoriatic arthritis.

Lilly Features it's Rheumatoid and Psoriasis Biologics at ACR 2016

Save

Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.

Janssen's Portfolio of New Biologics Roll Out for ACR 2016

Save

Janssen has announced the listings for it's presentations at the upcoming annual ACR/ARHP 2016 meeting in Washington.

Agressive Early Treatment Prevents Rapid Bone Loss in Rheumatoid Arthritis

Save

The International Osteoporosis Foundation has established the Chronic Inflammation and Bone Structure (CIBS) Working Group to address bone loss in rheumatoid arthritis (RA) and the role of biologic therapies. They conclude that early and aggressive treatment with biologic disease-modifying anti-rheumatic drugs will help prevent progressive bone loss in patients with RA.

Do Statins Reduce Cardiovascular Disease in Rheumatoid Arthritis?

Save

RA increases CV risk considerably. But whose responsibility is it to manage CV risk in RA patients?

Enbrel Approved for Pediatric Chronic Plaque Psoriasis

Save

Etanercept (Enbrel) received FDA approval Friday for use in children with moderate to severe, chronic plaque psoriasis.  Previously approved for adults with plaque psoriasis the new indication will be for chronic plaque psoriasis for those over age 4 years.

Decreased CD4 T Cells with Rituximab Infusions

Save

Rituximab (RTX) is a monoclonal antibody directed against the CD20 antigen on B cells and when administered causes a marked depletion of CD20+ B cells.